GlobeNewswire

Saniona Updates Tesomet Clinical Development Timelines Based on Manufacturing Feedback from U.S. FDA

Share

PRESS RELEASE

April 22, 2021

Saniona (OMX: SANION), a clinical stage biopharmaceutical company focused on rare diseases, today announced that it received feedback from the U.S. Food and Drug Administration (FDA) regarding its proposed chemistry, manufacturing and controls (CMC) plans for Tesomet. In preparation for Phase 2b through Phase 3 clinical trials and eventual commercialization, Saniona has undertaken multiple steps to optimize Tesomet, including transitioning from tablets to capsules. The company requested FDA feedback,and the FDA agreed with the company’s proposalbut requested additional information regarding Tesomet manufacturing. Saniona anticipates that addressing these requests will delay the start of the Phase 2b trials of Tesomet for Prader-Willi syndrome (PWS) and hypothalamic obesity (HO) into the second half of 2021.

Tesomet is an investigational fixed-dose combination of tesofensine (a triple monoamine reuptake inhibitor) and metoprolol (a beta-1 selective blocker). In preparation for Phase 2b through Phase 3 clinical trials and eventual commercialization, Saniona has taken multiple steps to optimize the manufacturing of Tesomet, including transitioning from tablets to capsules. The company chose to utilize a capsule form because some individuals with PWS and HO have a tendency to chew tablets, which would disrupt the performance of the fixed-dose combination. The Tesomet capsules contain the two active ingredients as microspheres, which are expected to minimize the impact of chewing or biting. Additionally, capsules are generally easier to swallow than tablets and facilitate the development of multiple dosage strength options.

Saniona requested a meeting with the FDA to get feedback on its manufacturing plans prior to initiating its clinical program. The FDA stated that it agrees with Saniona’s CMC development plan for Tesomet capsules as related to the proposed Phase 2b clinical trials. However, the agency requested additional information related to the manufacturing of the Tesomet capsules. No additional clinical trials will be required to obtain these data; however, gathering this information will delay the initiation of the Phase 2b clinical trials of Tesomet in PWS and HO into the second half of 2021.

“While we are disappointed to delay the initiation of our Phase 2b clinical trials of Tesomet in PWS and HO, we are encouraged that we have clear agreement from the FDA regarding our development plans as they relate to the manufacturing of these new Tesomet capsules,” said Kyle Haraldsen, Chief Technical Operations Officer for Saniona. “We believe that the work we are doing to optimize Tesomet and align with the FDA on manufacturing will enable us to move more expeditiously through our clinical trials, so that we may bring Tesomet to patients as quickly as possible.” 

For more information, please contact
Trista Morrison, Chief Communications Officer, Saniona. Office: + 1 (781) 810-9227. Email: trista.morrison@saniona.com

This information is such information as Saniona AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 01:00 CEST on 22 April 2021.

About Saniona
Saniona is a biopharmaceutical company focused on discovering, developing, and delivering innovative treatments for rare disease patients around the world. The company’s lead product candidate, Tesomet, is in mid-stage clinical trials for hypothalamic obesity and Prader-Willi syndrome, severe rare disorders characterized by uncontrollable hunger and intractable weight gain. Saniona’s robust drug discovery engine has generated a library now consisting of more than 20,000 proprietary modulators of ion channels, a significantly untapped drug class that is scientifically validated. Lead candidate SAN711 is entering Phase 1 for rare neuropathic disorders, with SAN903 for rare inflammatory and fibrotic disorders advancing through preclinical development. Led by an experienced scientific and operational team, Saniona has an established research organization in Copenhagen, Denmark and is building its corporate office in the Boston, Massachusetts area, U.S. The company’s shares are listed on Nasdaq Stockholm Small Cap (OMX: SANION). Read more at www.saniona.com.

About Tesomet
Tesomet is an investigational fixed-dose combination therapy of tesofensine (a triple monoamine reuptake inhibitor) and metoprolol (a beta-1 selective blocker). Saniona is advancing Tesomet for hypothalamic obesity and Prader-Willi syndrome, two severe rare disorders characterized by obesity and loss of appetite control. The programs are currently in clinical development. Saniona holds worldwide rights to Tesomet and is actively evaluating opportunities to advance this treatment globally.

Attachment


About GlobeNewswire

GlobeNewswire
GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://globenewswire.com

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire

Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire

Yara International ASA ex-dividend NOK 20 today7.5.2021 08:01:00 CEST | Press release

Oslo, 7 May 2021: Shares in Yara International ASA will be traded ex-dividend NOK 20 as of today, 7 May 2021. Contact Thor Giæver, Investor Relations Cellular: (+47) 480 75 356 E-mail: thor.giaver@yara.com About Yara Yara grows knowledge to responsibly feed the world and protect the planet. Supporting our vision of a world without hunger and a planet respected, we pursue a strategy of sustainable value growth, promoting climate-friendly crop nutrition and zero-emission energy solutions. Yara’s ambition is focused on growing a climate positive food future that creates value for our customers, shareholders and society at large and delivers a more sustainable food value chain. To achieve our ambition, we have taken the lead in developing digital farming tools for precision farming, and work closely with partners throughout the food value chain to improve the efficiency and sustainability of food production. Through our focus on clean ammonia production, we aim to enable the hydrogen econo

Yara International ASA eks. utbytte kr 20 i dag7.5.2021 08:01:00 CEST | Pressemelding

Oslo, 7. mai 2021:Aksjene i Yara International ASA noteres eks. utbytte på kr 20fra og med i dag, 7. mai 2021. Kontakt Thor Giæver, Investorkontakt Mobil: (+47) 480 75 356 E-post: thor.giaver@yara.com Om Yara Vår visjon om en verden uten sult ligger bak vår strategi som fremmer bærekraftig verdiskaping gjennom klimavennlig plantenæring og nullutslippsløsninger for energisektoren. Yaras ambisjon er å bidra til en klimapositiv fremtid for verdens matproduksjon. Slik skaper vi verdier for kundene våre, aksjonærene og samfunnet rundt oss. For å nå dette målet, leder vi an i utviklingen av digitale verktøy for presisjonslandbruk. Vi samarbeider tett med andre aktører i verdikjeden for at verdens matproduksjon skal bli mest mulig effektiv og bærekraftig. Vår satsing på grønn ammoniakk har som ambisjon å muliggjøre hydrogenøkonomien og bidra til et grønt skifte innen shipping, produksjon av plantenæring og andre energiintensive industrier. Yara ble grunnlagt i 1905 for å møte matmangelen i Eu

AB Klaipėdos nafta preliminary revenue for April 20217.5.2021 08:00:00 CEST | Press release

The preliminary sales revenue of the Company’s oil terminals for April 2021 comprises EUR 0.9 million and is lower by EUR 2.2 million or by 71 % compared to April of 2020. The preliminary sales revenue of the Company’s oil terminals for the four months of 2021 comprises EUR 6.3 million and is lower by 41 % compared to the same period of 2020. The preliminary sales revenue of the Company’s Klaipėda LNG terminal for April 2021 comprises EUR 2.9 million (during the same month of 2020 – EUR 3.4 million). Klaipėda LNG terminal revenue from regulated activities consists of the regasification tariff fixed part (for booked annual capacities), variable part for amount of re-gasified LNG and reloading revenue. The level of Klaipėda LNG terminal revenue (for booked annual capacities) does not depend on regasification volume. Revenue is confirmed by the National Energy Regulatory Council (NERC) based on the approved methodology of State regulated prices in the natural gas sector and is calculated

Yara Announces the Commercial Launch of Agoro Carbon Alliance, enabling global farm decarbonization7.5.2021 08:00:00 CEST | Press release

The new farm decarbonizationbusiness has operations and partnerships across four continents Oslo, Norway, May 7, 2021 - Yara, a leading crop nutrition solutions provider, today announced the commercial launch of Agoro Carbon Alliance, a global business created for farmers to earn additional revenue from positive climate action. By adopting climate-positive practices farmers can produce Farm Carbon Credits or climate-smart certified crops and help to decarbonize food supply chains. Agoro Carbon puts farmers at the center of the solution by incentivizing and enabling them to change practices and connecting them to the growing number of businesses looking for ways to achieve their climate pledges. Agoro Carbon will support farmers with the agronomical expertise and practical support to successfully sequester carbon in the soil and reduce emissions from the field. This will in turn generate high-quality, third-party certified carbon credits and increase farmers’ income. Farmers who join Ag

Årsstämma i JLT Mobile Computers AB (PUBL)7.5.2021 08:00:00 CEST | Pressemelding

Växjö, Sverige, 7:emaj2021 * * * Årsstämma i JLT Mobile Computers AB (publ), hölls torsdagen den 6 maj 2021. Årsstämman genomfördes enligt 20 och 22 §§ lagen (2020:198) om tillfälliga undantag för att underlätta genomförandet av bolags- och föreningsstämmor, innebärande att aktieägarna fått utöva sin rösträtt vi stämman endast genom att rösta på förhand, s.k. poströstning. Följande huvudsakliga beslut fattades: Årsstämman beslutade att fastställa framlagd resultat- och balansräkning för moderbolaget och koncernen. Årsstämman beslutade, i enlighet med styrelsens förslag, om utdelning till aktieägarna om 0,27 kronor per aktie för räkenskapsåret 2020. Avstämningsdag för utdelningen är den 10 maj 2021. Styrelseledamöterna och verkställande direktören beviljades ansvarsfrihet för 2020 års förvaltning. I enlighet med valberedningens förslag beslutades att styrelsen ska bestå av sex ledamöter utan suppleanter. Till styrelseledamöter för tiden intill slutet av nästa årsstämma omvaldes Ola Blom

Annual General Meeting of JLT Mobile Computers AB (Swedish only)7.5.2021 08:00:00 CEST | Press release

Växjö, Sverige, 7:emaj2021 * * * Årsstämma i JLT Mobile Computers AB (publ), hölls torsdagen den 6 maj 2021. Årsstämman genomfördes enligt 20 och 22 §§ lagen (2020:198) om tillfälliga undantag för att underlätta genomförandet av bolags- och föreningsstämmor, innebärande att aktieägarna fått utöva sin rösträtt vi stämman endast genom att rösta på förhand, s.k. poströstning. Följande huvudsakliga beslut fattades: Årsstämman beslutade att fastställa framlagd resultat- och balansräkning för moderbolaget och koncernen. Årsstämman beslutade, i enlighet med styrelsens förslag, om utdelning till aktieägarna om 0,27 kronor per aktie för räkenskapsåret 2020. Avstämningsdag för utdelningen är den 10 maj 2021. Styrelseledamöterna och verkställande direktören beviljades ansvarsfrihet för 2020 års förvaltning. I enlighet med valberedningens förslag beslutades att styrelsen ska bestå av sex ledamöter utan suppleanter. Till styrelseledamöter för tiden intill slutet av nästa årsstämma omvaldes Ola Blom

Pandora Trading Update for April 20217.5.2021 08:00:00 CEST | Press release

Pandora today releases a trading update for April 2021 as announced in the Q1 2021 Interim Financial Report. The trading update is, as the previous trading updates this year, released as a press release, and not a company announcement, per instructions from NASDAQ Copenhagen. Pandora has previously communicated that the company would, when relevant, release extraordinary trading updates due to the elevated uncertainty related to COVID-19. Pandora intents to cease issuing monthly trading updates when the percentage of temporarily closed stores reaches 15% or below. On average, around 25% of physical stores were temporarily closed due to COVID-19 in the month of April with around 20% of stores remaining closed today. Revenue in April 2021 was DKK 1,764 million, corresponding to 216% revenue growth in local currency vs April 2020. Key revenue metrics1 April 2021vs 2020vs 2019Organic growth, %214%32%Sell-out growth incl. temporarily closed stores, %123%7%Year-to-date 2021vs 2020vs 2019Orga